Fluticasone furoate, umeclidinium and vilanterol dry powder triple therapy inhaler

Description

In this Product Explainer, Respiratory Physician Dr Kwok Yan explains the role of fluticasone furoate, umeclidinium and vilanterol dry powder triple therapy inhaler for the maintenance treatment of asthma in adult patients who are not adequately controlled with an ICS+LABA (7 mins).

This educational activity was developed by Healthed at the request of and with funding from GSK.

PM-AU-FVU-OGM-220003 approved June 2022

Icon 2

NEXT LIVE Webcast

:
Days
:
Hours
:
Minutes
Seconds
Prof Dennis Lau

Prof Dennis Lau

Postural Orthostatic Tachycardia Syndrome – What You Need to Know

Prof Tony Attwood

Prof Tony Attwood

Autism Assessment in the GP Setting

Prof Brendon Yee, A/Prof Ralph Audehm

Prof Brendon Yee, A/Prof Ralph Audehm

Obstructive Sleep Apnoea – Practical Updates

Clinical A/Prof Greg Katsoulotos

Clinical A/Prof Greg Katsoulotos

Asthma Cases

Join us for the next free webcast for GPs and healthcare professionals

High quality lectures delivered by leading independent experts

Dr Kwok Yan

expert

Dr Kwok Yan

Respiratory Physician

Date published: 14 June 2022